Iovance Biotherapeutics (NASDAQ: IOVA) is a biotech company with an innovative approach to developing cancer medicines.

Infiltrating Lymphocyte Scoring Improves Progression Risk Prediction in Stage II Melanoma: A Retrospective Cohort Study,” published in the March 2025 issue of Journal of the American Academy of ...

Rick Schneider is a family man — a husband and doting father to three girls. He’s also an outdoorsman who loves to bike, hike ...

Xcell Biosciences Australia PTY LTD (Xcellbio), an affiliate of Xcell Biosciences, Inc., a platform company focused on cell and gene therapy applications, and Royal Perth Hospital announced a ...

肿瘤浸润调节性T细胞（Tumor-infiltrating regulatory T cells，TI-Treg cells）是肿瘤微环境中抑制抗肿瘤免疫并促进肿瘤进展的关键免疫细胞。尽管已有多种疗法旨在靶向TI-Treg细胞，然而大多数治疗效果不佳 ...

Iovance Biotherapeutics develops therapies that harness the power of tumor-infiltrating lymphocytes (TILs), immune cells that can target and destroy cancer cells. Iovance's TIL-based treatments ...

Through this agreement, Xcellbio scientists will work with the Royal Perth Hospital team to develop an automated TIL manufacturing process based on AVATAR platform that achieves key goals for cell ...

Tumor inflitrating lymphocyte therapies are a promising type of cellular immunotherapy used to treat a broad range of solid ...

Instil Bio is pivoting from tumor-infiltrating lymphocytes to in-licensed bispecifics, targeting PD-L1 and VEGF with SYN-2510, aiming to capitalize on promising immunotherapy trends. SYN-2510 ...

(NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today provided an ...